98%
921
2 minutes
20
Background: The overdose crisis is increasingly characterized by opioid and stimulant co-use. Despite effective pharmacologic treatment for both opioid use disorder (OUD) and contingency management for stimulant use disorders, most individuals with these co-occurring conditions are not engaged in treatment. Hospitalization is an important opportunity to engage patients and initiate treatment, however existing hospital addiction care is not tailored for patients with co-use and may not meet the needs of this population.
Methods: Semi-structured interviews were conducted with hospital providers about their experiences and perspectives treating patients with opioid and stimulant co-use. We used directed content analysis to identify common experiences and opportunities to improve hospital-based treatment for patients with co-use.
Results: From qualitative interviews with 20 providers, we identified 4 themes describing how co-use complicated hospital-based substance use treatment: (1) patients' unstable circumstances impacting the treatment plan, (2) co-occurring withdrawals are difficult to identify and treat, (3) providers holding more stigmatizing views of patients with co-use, and (4) stimulant use is often "ignored" in the treatment plans. Participants also described a range of potential opportunities to improve hospital-based treatment of co-use that fall into 3 categories: (1) provider practice changes, (2) healthcare system changes, and (3) development and validation of clinical tools and treatment approaches.
Conclusions: We identified unique challenges providing hospital addiction medicine care to patients who use both opioids and stimulants. These findings inform the development, implementation, and testing of hospital-based interventions for patients with co-use.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11151687 | PMC |
http://dx.doi.org/10.1177/29767342231221060 | DOI Listing |
Am J Psychiatry
September 2025
Michigan Innovations in Addiction Care Through Research and Education (MI-ACRE) Program, Department of Psychiatry, University of Michigan, Ann Arbor.
Objective: While opioid overdose has begun to decrease in recent years, stimulant overdose has continued to increase and has not been adequately addressed. Unlike opioid use disorder, there are no medications approved by the U.S.
View Article and Find Full Text PDFArch Psychiatr Nurs
October 2025
University of Pittsburgh School of Nursing, Department of Health and Community Systems, 3500 Victoria St. Pittsburgh, PA 15213, United States of America. Electronic address:
Background: Women veterans are at risk for substance use and substance use disorders, although there remains limited data on substance use in women veterans.
Methods: A secondary analysis of data from the National Survey on Drug Use and Health from 2015 to 2019 and 2021 was conducted to compare women veterans with women non-veterans and men veterans on substance-related outcomes, including lifetime substance use, frequency of past 30-day substance use, and past-year substance use disorders for cannabis, opioids, and stimulants.
Results: From 2015 to 2019, women veterans were about 53 % and 24 % more likely to have used cannabis in their lifetime compared to women non-veterans and men veterans, respectively.
Sci Total Environ
September 2025
Department of Civil and Environmental Engineering, University of Massachusetts Lowell, MA 01854, USA. Electronic address:
The presence of drugs of abuse in freshwater systems is an emerging environmental concern with potential ecological implications. This systematic literature review examines the global occurrence and distribution of ten highly consumed drugs in rivers, including stimulants (cocaine, amphetamine, methamphetamine, 3,4-methylenedioxy-methamphetamine or MDMA, ketamine) and opioids (codeine, fentanyl, methadone, morphine, tramadol). Using a multi-stage screening process, we identified peer-reviewed articles published between 2012 and 2022, yielding a final dataset covering 225 unique rivers and 865 distinct sampling points across diverse geographic regions.
View Article and Find Full Text PDFJ Arthroplasty
September 2025
Cleveland Clinic Foundation, Department of Orthopaedic Surgery, Cleveland, OH, USA 44195. Electronic address:
Introduction: The NarxCare Overdose Risk Score (ORS) is a measure of prescription drug use with scores ranging from 0 to 999, and higher scores suggest worse prescription drug use patterns, including opioids, sedatives, and stimulants. We aimed to evaluate the association of preoperative NarxCare ORS with clinically meaningful improvements in patient-reported outcome measures (PROMs) and satisfaction at one year.
Methods: Patients undergoing primary total knee arthroplasty (TKA) at an academic healthcare system (November 2018 to December 2022) were included.
Drug Alcohol Depend
August 2025
RTI International, USA.
Objective: Cocaine- and opioid-related overdose deaths have increased among Black people, which makes identifying effective treatments for Black people a high priority. We investigated the comparative effectiveness of behavioral treatments among Black adults who use cocaine and/or opioids.
Methods: Identified multisite randomized clinical trials (RCTs) of behavioral interventions that targeted substance use, had participants who self-identified as Black, and included cocaine use outcome measures from the National Drug Abuse Treatment Clinical Trials Network (CTN) datashare.